IpIBA seminar series 2022/2023“Exploiting nanobodies targeting ABCC3 for glioblastoma immunoguided applications.” Tuesday, November 29th 2022 From 9:30 to 10:30 Glioblastoma is the most aggressive primary brain tumor […]